<DOC>
	<DOCNO>NCT02911350</DOCNO>
	<brief_summary>The purpose study determine combination therapy Hormone , Paclitaxel Radiation therapy effective treatment locally advanced prostate cancer</brief_summary>
	<brief_title>Safety Study Combination Hormone Therapy , Paclitaxel Radiation Therapy Treat Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Any one follow characteristic qualify patient T2/T3 prostate cancer eligibility current study : Biopsy proven prostate cancer Gleason score &gt; 7 Pathologic stag TXN1 ( MRI CT ) Prostatespecific antigen ( PSA ) &gt; 10 ng/ml do within month prior study entry ( day first hormonal ablation ) &gt; 10 day prostate biopsy . In addition patient must also : Performance status &lt; 2 Hemoglobin &gt; 11 gram per deciliter ( g/dL ) , White blood cell ( WBC ) &gt; 4000 platelet count &gt; 100.000/l No evidence synchronous primary . Prior malignancy exclude patient disease free &gt; 5 year . Prior concurrent basal cell noninvasive squamous carcinoma skin eligible Received hormone therapy follow combination le 3 month Lupron / Flutamide Zoladex/ Flutamide Lupron/ Casodex Zoladex/ Casodex Clinical stage T1N0 , PSA &lt; 10 , Gleason score less 7 . Evidence distant metastasis Previous surgery prostate cancer ( radical prostatectomy ) . Current treatment ketoconazole , cimetidine hormone therapy 3 month prior inclusion protocol prostate cancer Major medical psychiatric illness , investigator 's opinion may prevent completion study interfere follow . Bilirubin &gt; 1.5 Prior chemotherapy allow</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>